Value20202021202220232024TTMSelling/general/admin expenses14.72 M17.14 M17.83 M22.48 M22.11 M16.92 MResearch & development47.48 M65.5 M84.41 M73.7 M54.04 M29.05 MOperating income57.81 M73.52 M65.46 M78.1 M76.32 M49.78 MNon-Operating Income, Total5.94 M2.73 M444 K5.25 M6.4 M4.53 MInterest expense, net of interest capitalized4.01 M2.86 M1.73 M459 K137 K109 KNon-Operating Income, excl. Interest Expenses1.93 M-132 K-1.28 M4.79 M6.26 M4.42 MUnusual income/expense——————Pretax income63.74 M88.4 M122.4 M102.5 M70 M108.89 MEquity in earnings2.54 M0————Taxes004.44 M00—Non-controlling/minority interest——————After tax other income/expense——————Net income before discontinued operations63.74 M76.25 M69.46 M72.85 M69.92 M47.32 MDiscontinued operations——————Net income63.74 M76.25 M69.46 M72.85 M69.92 M47.32 MDilution adjustment24.25 M24.28 M0———Preferred dividends12.12 M12.14 M0———Diluted net income available to common stockholders75.87 M88.39 M69.46 M72.85 M69.92 M47.32 MBasic earnings per share (Basic EPS)—-0.83-0.46-0.44-0.38-0.23Diluted earnings per share (Diluted EPS)—-0.83-0.46-0.44-0.38-0.23Average basic shares outstanding—106.24 M150.94 M165.96 M185.61 M759.23 MDiluted shares outstanding—106.24 M150.94 M165.96 M185.61 M759.23 MEBITDA——————EBIT——————Cost of revenue——————Other cost of goods sold——————Depreciation & amortization (cash flow)1.77 M801 K1.35 M-796 K-1.74 M-571 K
Arbutus Biopharma Corporation
Arbutus Biopharma Corporation is a publicly traded Canadian biopharmaceutical company with an expertise in liposomal drug delivery and RNA interference, and is developing drugs for hepatitis B infection.
It is headquartered in Warminster, Pennsylvania. The company was formerly known as Tekmira, which was spun out of Inex Pharmaceuticals in 2007.